Lauren Brady, Lisa F Newcomb, Kehao Zhu, Yingye Zheng, Hilary Boyer, Navonil De Sarkar, Jesse K McKenney, James D Brooks, Peter R Carroll, Atreya Dash, William J Ellis, Christopher P Filson, Martin E Gleave, Michael A Liss, Frances Martin, Todd M Morgan, Ian M Thompson, Andrew A Wagner, Colin C Pritchard, Daniel W Lin, Peter S Nelson
BACKGROUND: Pathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low-risk PC on active surveillance, and assess whether pathogenic germline mutations associate with grade reclassification or adverse pathology, recurrence, or metastases, in men treated after initial surveillance. METHODS: Men prospectively enrolled in the Canary Prostate Active Surveillance Study (PASS) were retrospectively sampled for the study...
April 25, 2022: Cancer Medicine